Information Provided By: 
Fly News Breaks for June 2, 2015
PBYI
Jun 2, 2015 | 07:41 EDT
UBS said Puma Biotechnology is an undervalued asset following the release of data points at the ASCO meeting. The firm said the meeting reinforced the positive aspects of its neratinib data. UBS believes the data is better than the market is giving credit for and is not worried about the drug's approvability. UBS reiterated its Buy rating and $300 price target on Puma Biotechnology shares.
News For PBYI From the Last 2 Days
There are no results for your query PBYI
